
Grünenthal Report 2022/23
4,400 dedicated employees – more than 75 years of experience in developing innovative medicines – a fully integrated setup including R&D and five manufacturing sites. These are some of the key figures that have helped us become the leading pain management company in Europe and Latin America.
Our Grünenthal Report provides information about our key objectives and activities, as well as our recent business development highlights and financial performance. Download Full Report PDF